
Opinion|Videos|November 29, 2024
Novel Therapeutics in Development for CSU
Key Takeaways
- Steroids offer rapid symptom relief in CSU but are generally reserved for short-term use due to adverse effects.
- Long-term systemic steroid use can lead to significant side effects, including osteoporosis, hypertension, and glucose intolerance.
Panelists discuss how the integration of advanced treatments such as biologics and Bruton tyrosine kinase (BTK) inhibitors can bridge the gap in managing chronic spontaneous urticaria (CSU) for patients unresponsive to antihistamines.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Can you describe what you see as the current and future role of advanced treatments such as biologics and BTK inhibitors in CSU management?
- What gap currently exists in transitioning from antihistamine cycling to a biologic?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Inhaled Treprostinil Improves IPF Outcomes in Phase 3 TETON-1 Trial
2
Diabetes Technology at a Turning Point: What’s New and What’s Next, With Rachael Sood, NP
3
What We Still Don't Know: Gaps, Phototherapy, and the Future of Pediatric Eczema Care
4
When and How to Escalate Pediatric Atopic Dermatitis Treatment
5





















































